Sanofi's eczema drug is four-time blockbuster

Sanofi drug Dupixent, which Leo Pharma hopes to challenge with its tralokinumab treatment, has surpassed USD 4bn in sales.
Photo: Gonzalo Fuentes/Reuters/Ritzau Scanpix
Photo: Gonzalo Fuentes/Reuters/Ritzau Scanpix

The resurgence of the coronavirus in many countries has not put a damper on the growth of Sanofi's eczema drug Dupixent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading